U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Links from PMC

Prednisolone response

MedGen UID:
881196
•Concept ID:
CN236771
•
Sign or Symptom
Drug:
prednisolone
MedGen UID:
10892
•Concept ID:
C0032950
•
Pharmacologic Substance
A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisolone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04) [from NCI]
prednisolone

Professional guidelines

PubMed

EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update.
Hellmich B, Sanchez-Alamo B, Schirmer JH, Berti A, Blockmans D, Cid MC, Holle JU, Hollinger N, Karadag O, Kronbichler A, Little MA, Luqmani RA, Mahr A, Merkel PA, Mohammad AJ, Monti S, Mukhtyar CB, Musial J, Price-Kuehne F, Segelmark M, Teng YKO, Terrier B, Tomasson G, Vaglio A, Vassilopoulos D, Verhoeven P, Jayne D
Ann Rheum Dis 2024 Jan 2;83(1):30-47. doi: 10.1136/ard-2022-223764. PMID: 36927642
The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.
Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, Marinò M, Vaidya B, Wiersinga WM; EUGOGO †
Eur J Endocrinol 2021 Aug 27;185(4):G43-G67. doi: 10.1530/EJE-21-0479. PMID: 34297684
British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.
Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H; IBD guidelines eDelphi consensus group, Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB
Gut 2019 Dec;68(Suppl 3):s1-s106. Epub 2019 Sep 27 doi: 10.1136/gutjnl-2019-318484. PMID: 31562236Free PMC Article

Curated

DailyMed Drug Label, prednisolone, 2007

Recent clinical studies

Etiology

Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group.
Sato A, Hatta Y, Imai C, Oshima K, Okamoto Y, Deguchi T, Hashii Y, Fukushima T, Hori T, Kiyokawa N, Kato M, Saito S, Anami K, Sakamoto T, Kosaka Y, Suenobu S, Imamura T, Kada A, Saito AM, Manabe A, Kiyoi H, Matsumura I, Koh K, Watanabe A, Miyazaki Y, Horibe K
Lancet Haematol 2023 Jun;10(6):e419-e432. Epub 2023 May 8 doi: 10.1016/S2352-3026(23)00072-8. PMID: 37167992
Systemic cytokines and GlycA discriminate disease status and predict corticosteroid response in HTLV-1-associated neuroinflammation.
Assone T, Menezes SM, de Toledo Gonçalves F, Folgosi VA, da Silva Prates G, Dierckx T, Braz M, Smid J, Haziot ME, Marcusso RMN, Dahy FE, Vanderlinden E, Claes S, Schols D, Bruhn R, Murphy EL, Penalva de Oliveira AC, Daelemans D, Vercauteren J, Casseb J, Van Weyenbergh J
J Neuroinflammation 2022 Dec 8;19(1):293. doi: 10.1186/s12974-022-02658-w. PMID: 36482436Free PMC Article
Protocol for ICiCLe-ALL-14 (InPOG-ALL-15-01): a prospective, risk stratified, randomised, multicentre, open label, controlled therapeutic trial for newly diagnosed childhood acute lymphoblastic leukaemia in India.
Das N, Banavali S, Bakhshi S, Trehan A, Radhakrishnan V, Seth R, Arora B, Narula G, Sinha S, Roy P, Gogoi MP, Chatterjee S, Abraham B, Das P, Saha V, Krishnan S
Trials 2022 Jan 31;23(1):102. doi: 10.1186/s13063-022-06033-1. PMID: 35101099Free PMC Article
Discontinuation of L-asparaginase and poor response to prednisolone are associated with poor outcome of ETV6-RUNX1-positive pediatric B-cell precursor acute lymphoblastic leukemia.
Usami I, Imamura T, Takahashi Y, Suenobu SI, Hasegawa D, Hashii Y, Deguchi T, Hori T, Shimada A, Kato K, Ito E, Moriya-Saito A, Kawasaki H, Hori H, Yumura-Yagi K, Hara J, Sato A, Horibe K; Japan Association of Childhood Leukemia Study Group (JACLS)
Int J Hematol 2019 Apr;109(4):477-482. Epub 2019 Jan 28 doi: 10.1007/s12185-019-02599-w. PMID: 30689137
Expression of certain leukemia/lymphoma related microRNAs and its correlation with prognosis in childhood acute lymphoblastic leukemia.
Nemes K, Csóka M, Nagy N, Márk Á, Váradi Z, Dankó T, Kovács G, Kopper L, Sebestyén A
Pathol Oncol Res 2015 Jul;21(3):597-604. Epub 2014 Nov 12 doi: 10.1007/s12253-014-9861-z. PMID: 25388103

Diagnosis

Immunophenotypic and Cytogenetic Characteristics of Pediatric Acute Lymphoblastic Leukemia: A Burden Estimation Study from Eastern India.
Sarkar SD, Maiti D, Ghosh A, Ganguly M, Ahmed N
Indian J Public Health 2024 Jan 1;68(1):21-25. Epub 2024 Apr 4 doi: 10.4103/ijph.ijph_889_23. PMID: 38847628
Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group.
Sato A, Hatta Y, Imai C, Oshima K, Okamoto Y, Deguchi T, Hashii Y, Fukushima T, Hori T, Kiyokawa N, Kato M, Saito S, Anami K, Sakamoto T, Kosaka Y, Suenobu S, Imamura T, Kada A, Saito AM, Manabe A, Kiyoi H, Matsumura I, Koh K, Watanabe A, Miyazaki Y, Horibe K
Lancet Haematol 2023 Jun;10(6):e419-e432. Epub 2023 May 8 doi: 10.1016/S2352-3026(23)00072-8. PMID: 37167992
Protocol for ICiCLe-ALL-14 (InPOG-ALL-15-01): a prospective, risk stratified, randomised, multicentre, open label, controlled therapeutic trial for newly diagnosed childhood acute lymphoblastic leukaemia in India.
Das N, Banavali S, Bakhshi S, Trehan A, Radhakrishnan V, Seth R, Arora B, Narula G, Sinha S, Roy P, Gogoi MP, Chatterjee S, Abraham B, Das P, Saha V, Krishnan S
Trials 2022 Jan 31;23(1):102. doi: 10.1186/s13063-022-06033-1. PMID: 35101099Free PMC Article
Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol.
Stutterheim J, de Lorenzo P, van der Sluis IM, Alten J, Ancliffe P, Attarbaschi A, Aversa L, Boer JM, Biondi A, Brethon B, Diaz P, Cazzaniga G, Escherich G, Ferster A, Kotecha RS, Lausen B, Leung AW, Locatelli F, Silverman L, Stary J, Szczepanski T, van der Velden VHJ, Vora A, Zuna J, Schrappe M, Valsecchi MG, Pieters R
Eur J Cancer 2022 Jan;160:72-79. Epub 2021 Nov 13 doi: 10.1016/j.ejca.2021.10.004. PMID: 34785111
Idiopathic sclerosing orbital inflammation.
Hsuan JD, Selva D, McNab AA, Sullivan TJ, Saeed P, O'Donnell BA
Arch Ophthalmol 2006 Sep;124(9):1244-50. doi: 10.1001/archopht.124.9.1244. PMID: 16966618

Therapy

Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group.
Sato A, Hatta Y, Imai C, Oshima K, Okamoto Y, Deguchi T, Hashii Y, Fukushima T, Hori T, Kiyokawa N, Kato M, Saito S, Anami K, Sakamoto T, Kosaka Y, Suenobu S, Imamura T, Kada A, Saito AM, Manabe A, Kiyoi H, Matsumura I, Koh K, Watanabe A, Miyazaki Y, Horibe K
Lancet Haematol 2023 Jun;10(6):e419-e432. Epub 2023 May 8 doi: 10.1016/S2352-3026(23)00072-8. PMID: 37167992
Protocol for ICiCLe-ALL-14 (InPOG-ALL-15-01): a prospective, risk stratified, randomised, multicentre, open label, controlled therapeutic trial for newly diagnosed childhood acute lymphoblastic leukaemia in India.
Das N, Banavali S, Bakhshi S, Trehan A, Radhakrishnan V, Seth R, Arora B, Narula G, Sinha S, Roy P, Gogoi MP, Chatterjee S, Abraham B, Das P, Saha V, Krishnan S
Trials 2022 Jan 31;23(1):102. doi: 10.1186/s13063-022-06033-1. PMID: 35101099Free PMC Article
Discontinuation of L-asparaginase and poor response to prednisolone are associated with poor outcome of ETV6-RUNX1-positive pediatric B-cell precursor acute lymphoblastic leukemia.
Usami I, Imamura T, Takahashi Y, Suenobu SI, Hasegawa D, Hashii Y, Deguchi T, Hori T, Shimada A, Kato K, Ito E, Moriya-Saito A, Kawasaki H, Hori H, Yumura-Yagi K, Hara J, Sato A, Horibe K; Japan Association of Childhood Leukemia Study Group (JACLS)
Int J Hematol 2019 Apr;109(4):477-482. Epub 2019 Jan 28 doi: 10.1007/s12185-019-02599-w. PMID: 30689137
Expression of certain leukemia/lymphoma related microRNAs and its correlation with prognosis in childhood acute lymphoblastic leukemia.
Nemes K, Csóka M, Nagy N, Márk Á, Váradi Z, Dankó T, Kovács G, Kopper L, Sebestyén A
Pathol Oncol Res 2015 Jul;21(3):597-604. Epub 2014 Nov 12 doi: 10.1007/s12253-014-9861-z. PMID: 25388103
Idiopathic sclerosing orbital inflammation.
Hsuan JD, Selva D, McNab AA, Sullivan TJ, Saeed P, O'Donnell BA
Arch Ophthalmol 2006 Sep;124(9):1244-50. doi: 10.1001/archopht.124.9.1244. PMID: 16966618

Prognosis

Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group.
Sato A, Hatta Y, Imai C, Oshima K, Okamoto Y, Deguchi T, Hashii Y, Fukushima T, Hori T, Kiyokawa N, Kato M, Saito S, Anami K, Sakamoto T, Kosaka Y, Suenobu S, Imamura T, Kada A, Saito AM, Manabe A, Kiyoi H, Matsumura I, Koh K, Watanabe A, Miyazaki Y, Horibe K
Lancet Haematol 2023 Jun;10(6):e419-e432. Epub 2023 May 8 doi: 10.1016/S2352-3026(23)00072-8. PMID: 37167992
Systemic cytokines and GlycA discriminate disease status and predict corticosteroid response in HTLV-1-associated neuroinflammation.
Assone T, Menezes SM, de Toledo Gonçalves F, Folgosi VA, da Silva Prates G, Dierckx T, Braz M, Smid J, Haziot ME, Marcusso RMN, Dahy FE, Vanderlinden E, Claes S, Schols D, Bruhn R, Murphy EL, Penalva de Oliveira AC, Daelemans D, Vercauteren J, Casseb J, Van Weyenbergh J
J Neuroinflammation 2022 Dec 8;19(1):293. doi: 10.1186/s12974-022-02658-w. PMID: 36482436Free PMC Article
Discontinuation of L-asparaginase and poor response to prednisolone are associated with poor outcome of ETV6-RUNX1-positive pediatric B-cell precursor acute lymphoblastic leukemia.
Usami I, Imamura T, Takahashi Y, Suenobu SI, Hasegawa D, Hashii Y, Deguchi T, Hori T, Shimada A, Kato K, Ito E, Moriya-Saito A, Kawasaki H, Hori H, Yumura-Yagi K, Hara J, Sato A, Horibe K; Japan Association of Childhood Leukemia Study Group (JACLS)
Int J Hematol 2019 Apr;109(4):477-482. Epub 2019 Jan 28 doi: 10.1007/s12185-019-02599-w. PMID: 30689137
Expression of certain leukemia/lymphoma related microRNAs and its correlation with prognosis in childhood acute lymphoblastic leukemia.
Nemes K, Csóka M, Nagy N, Márk Á, Váradi Z, Dankó T, Kovács G, Kopper L, Sebestyén A
Pathol Oncol Res 2015 Jul;21(3):597-604. Epub 2014 Nov 12 doi: 10.1007/s12253-014-9861-z. PMID: 25388103
Treatment of children with acute lymphoblastic leukemia in India using a BFM protocol.
Bajel A, George B, Mathews V, Viswabandya A, Kavitha ML, Srivastava A, Chandy M
Pediatr Blood Cancer 2008 Nov;51(5):621-5. doi: 10.1002/pbc.21671. PMID: 18688848

Clinical prediction guides

Impact of minimal residual disease on relapse in childhood acute lymphoblastic leukemia: Lessons learnt from a tertiary cancer center in India.
Mishra V, Jain S, Anand V, Malhotra P, Tejwani N, Kapoor G
Pediatr Hematol Oncol 2023;40(6):517-528. Epub 2023 Mar 17 doi: 10.1080/08880018.2023.2186553. PMID: 36930957
Systemic cytokines and GlycA discriminate disease status and predict corticosteroid response in HTLV-1-associated neuroinflammation.
Assone T, Menezes SM, de Toledo Gonçalves F, Folgosi VA, da Silva Prates G, Dierckx T, Braz M, Smid J, Haziot ME, Marcusso RMN, Dahy FE, Vanderlinden E, Claes S, Schols D, Bruhn R, Murphy EL, Penalva de Oliveira AC, Daelemans D, Vercauteren J, Casseb J, Van Weyenbergh J
J Neuroinflammation 2022 Dec 8;19(1):293. doi: 10.1186/s12974-022-02658-w. PMID: 36482436Free PMC Article
Protocol for ICiCLe-ALL-14 (InPOG-ALL-15-01): a prospective, risk stratified, randomised, multicentre, open label, controlled therapeutic trial for newly diagnosed childhood acute lymphoblastic leukaemia in India.
Das N, Banavali S, Bakhshi S, Trehan A, Radhakrishnan V, Seth R, Arora B, Narula G, Sinha S, Roy P, Gogoi MP, Chatterjee S, Abraham B, Das P, Saha V, Krishnan S
Trials 2022 Jan 31;23(1):102. doi: 10.1186/s13063-022-06033-1. PMID: 35101099Free PMC Article
Treatment of children with acute lymphoblastic leukemia in India using a BFM protocol.
Bajel A, George B, Mathews V, Viswabandya A, Kavitha ML, Srivastava A, Chandy M
Pediatr Blood Cancer 2008 Nov;51(5):621-5. doi: 10.1002/pbc.21671. PMID: 18688848
Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study.
Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA
Thorax 2003 Aug;58(8):654-8. doi: 10.1136/thorax.58.8.654. PMID: 12885977Free PMC Article

Supplemental Content

Filter your results:

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Curated

    Consumer resources

    Reviews

    Related information

    • ClinVar
      Related medical variations
    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...